Journal of Clinical Immunology

, Volume 29, Issue 6, pp 752–760 | Cite as

Specific Immunotherapy to Birch Allergen Does not Enhance Suppression of Th2 Cells by CD4+CD25+ Regulatory T Cells During Pollen Season

  • Hanna Grindebacke
  • Pia Larsson
  • Kajsa Wing
  • Sabina Rak
  • Anna Rudin



The aim of this study was to investigate the suppressive capacity of CD25+ regulatory T cells on birch allergen-induced T-cell responses during the first birch pollen season after initiation of specific immunotherapy (SIT).


CD25pos and CD25neg T cells were purified from blood of birch-allergic SIT patients and birch-allergic controls, stimulated with birch pollen extract, and analyzed for T-cell proliferation and production of interferon gamma (IFN-γ), interleukin (IL)-5 and IL-10.


We show that allergen-induced proliferation and IFN-γ production were suppressed equally well by CD25pos T cells from SIT patients and controls, while the IL-5 production was not suppressed by either of the groups. IL-10 levels were higher in SIT patients relative to controls only when CD25neg and CD25pos were cultured together. Furthermore, neither FOXP3 levels nor proportions of CD25high T cells were enhanced in SIT patients compared to allergic controls.


These results suggest that the Th2-suppressive capacity of allergen-stimulated CD25pos Treg in vitro is not improved by SIT in spite of increased IL-10 production from T cells.


Human CD4+CD25+ regulatory T cells allergy immunotherapy suppression IL-10 



We are grateful to the study nurse Yvonne Bäckberg for skilfull assistance, and we thank all volunteers for donating blood to the study. This work was supported by the Medical Faculty, Göteborg University; the Swedish Research Council (grant K2002-745X-14455-01A); Vårdal Foundation; the Swedish Asthma and Allergy Association Research Foundation; and Göteborg Medical Society, Frimurare Barnhus-direktionen.


  1. 1.
    Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol. 1998;102:558–62.CrossRefPubMedGoogle Scholar
  2. 2.
    Golden DB, Kwiterovich KA, Kagey-Sobotka A, Valentine MD, Lichtenstein LM. Discontinuing venom immunotherapy: outcome after five years. J Allergy Clin Immunol. 1996;97:579–87.CrossRefPubMedGoogle Scholar
  3. 3.
    Arvidsson MB, Lowhagen O, Rak S. Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy. J Allergy Clin Immunol. 2002;109:777–83.CrossRefPubMedGoogle Scholar
  4. 4.
    Arvidsson MB, Lowhagen O, Rak S. Allergen specific immunotherapy attenuates early and late phase reactions in lower airways of birch pollen asthmatic patients: a double blind placebo-controlled study. Allergy. 2004;59:74–80.CrossRefPubMedGoogle Scholar
  5. 5.
    Bellinghausen I, Metz G, Enk AH, Christmann S, Knop J, Saloga J. Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface marker expression in venom-allergic subjects. Eur J Immunol. 1997;27:1131–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Akdis CA, Blesken T, Akdis M, Wuthrich B, Blaser K. Role of interleukin 10 in specific immunotherapy. J Clin Invest. 1998;102:98–106.CrossRefPubMedGoogle Scholar
  7. 7.
    Gehlhar K, Schlaak M, Becker W, Bufe A. Monitoring allergen immunotherapy of pollen-allergic patients: the ratio of allergen-specific IgG4 to IgG1 correlates with clinical outcome. Clin Exp Allergy. 1999;29:497–506.CrossRefPubMedGoogle Scholar
  8. 8.
    Jeannin P, Lecoanet S, Delneste Y, Gauchat JF, Bonnefoy JY. IgE versus IgG4 production can be differentially regulated by IL-10. J Immunol. 1998;160:3555–61.PubMedGoogle Scholar
  9. 9.
    Royer B, Varadaradjalou S, Saas P, Guillosson JJ, Kantelip JP, Arock M. Inhibition of IgE-induced activation of human mast cells by IL-10. Clin Exp Allergy. 2001;31:694–704.CrossRefPubMedGoogle Scholar
  10. 10.
    Takanaski S, Nonaka R, Xing Z, O’Byrne P, Dolovich J, Jordana M. Interleukin 10 inhibits lipopolysaccharide-induced survival and cytokine production by human peripheral blood eosinophils. J Exp Med. 1994;180:711–5.CrossRefPubMedGoogle Scholar
  11. 11.
    Buelens C, Verhasselt V, De Groote D, Thielemans K, Goldman M, Willems F. Interleukin-10 prevents the generation of dendritic cells from human peripheral blood mononuclear cells cultured with interleukin-4 and granulocyte/macrophage-colony-stimulating factor. Eur J Immunol. 1997;27:756–62.CrossRefPubMedGoogle Scholar
  12. 12.
    de Waal Malefyt R, Haanen J, Spits H, Roncarolo MG, te Velde A, Figdor C, et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med. 1991;174:915–24.CrossRefPubMedGoogle Scholar
  13. 13.
    Groux H, O’Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature. 1997;389:737–42.CrossRefPubMedGoogle Scholar
  14. 14.
    Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995;155:1151–64.PubMedGoogle Scholar
  15. 15.
    Yagi H, Nomura T, Nakamura K, Yamazaki S, Kitawaki T, Hori S, et al. Crucial role of FOXP3 in the development and function of human CD25+CD4+ regulatory T cells. Int Immunol. 2004;16:1643–56.CrossRefPubMedGoogle Scholar
  16. 16.
    Dieckmann D, Plottner H, Berchtold S, Berger T, Schuler G. Ex vivo isolation and characterization of CD4(+) CD25(+) T cells with regulatory properties from human blood. J Exp Med. 2001;193:1303–10.CrossRefPubMedGoogle Scholar
  17. 17.
    Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J, Enk AH. Identification and functional characterization of human CD4(+) CD25(+) T cells with regulatory properties isolated from peripheral blood. J Exp Med. 2001;193:1285–94.CrossRefPubMedGoogle Scholar
  18. 18.
    Powrie F, Carlino J, Leach MW, Mauze S, Coffman RL. A critical role for transforming growth factor-beta but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RB(low) CD4+ T cells. J Exp Med. 1996;183:2669–74.CrossRefPubMedGoogle Scholar
  19. 19.
    Asseman C, Mauze S, Leach MW, Coffman RL, Powrie F. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med. 1999;190:995–1004.CrossRefPubMedGoogle Scholar
  20. 20.
    Kearley J, Barker JE, Robinson DS, Lloyd CM. Resolution of airway inflammation and hyperreactivity after in vivo transfer of CD4+ CD25+ regulatory T cells is interleukin 10 dependent. J Exp Med. 2005;202:1539–47.CrossRefPubMedGoogle Scholar
  21. 21.
    Francis JN, Till SJ, Durham SR. Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol. 2003;111:1255–61.CrossRefPubMedGoogle Scholar
  22. 22.
    Gardner LM, Thien FC, Douglass JA, Rolland JM, O’Hehir RE. Induction of T ‘regulatory’ cells by standardized house dust mite immunotherapy: an increase in CD4+CD25+ interleukin-10+ T cells expressing peripheral tissue trafficking markers. Clin Exp Allergy. 2004;34:1209–19.CrossRefPubMedGoogle Scholar
  23. 23.
    Jutel M, Akdis M, Budak F, Aebischer-Casaulta C, Wrzyszcz M, Blaser K, et al. IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol. 2003;33:1205–14.CrossRefPubMedGoogle Scholar
  24. 24.
    Bellinghausen I, Klostermann B, Knop J, Saloga J. Human CD4+CD25+ T cells derived from the majority of atopic donors are able to suppress TH1 and TH2 cytokine production. J Allergy Clin Immunol. 2003;111:862–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Ling EM, Smith T, Nguyen XD, Pridgeon C, Dallman M, Arbery J, et al. Relation of CD4+CD25+ regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease. Lancet. 2004;363:608–15.CrossRefPubMedGoogle Scholar
  26. 26.
    Grindebacke H, Wing K, Andersson AC, Suri-Payer E, Rak S, Rudin A. Defective suppression of Th2 cytokines by CD4+CD25+ regulatory T cells in birch allergics during birch pollen season. Clin Exp Allergy. 2004;34:1364–72.CrossRefPubMedGoogle Scholar
  27. 27.
    Maggi L, Santarlasci V, Liotta F, Frosali F, Angeli R, Cosmi L, et al. Demonstration of circulating allergen-specific CD4+CD25highFoxp3+ T-regulatory cells in both nonatopic and atopic individuals. J Allergy Clin Immunol. 2007;120:429–36.CrossRefPubMedGoogle Scholar
  28. 28.
    Varney VA, Gaga M, Frew AJ, Aber VR, Kay AB, Durham SR. Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. BMJ. 1991;302:265–9.CrossRefPubMedGoogle Scholar
  29. 29.
    Baecher-Allan C. Human CD25high Tregs: isolation by beads versus by FACS sorting. Clin Immunol. 2006;120:234–5.CrossRefPubMedGoogle Scholar
  30. 30.
    Wing K, Lindgren S, Kollberg G, Lundgren A, Harris RA, Rudin A, et al. CD4 T cell activation by myelin oligodendrocyte glycoprotein is suppressed by adult but not cord blood CD25+ T cells. Eur J Immunol. 2003;33:579–87.CrossRefPubMedGoogle Scholar
  31. 31.
    Karlsson H, Hessle C, Rudin A. Innate immune responses of human neonatal cells to bacteria from the normal gastrointestinal flora. Infect Immun. 2002;70:6688–96.CrossRefPubMedGoogle Scholar
  32. 32.
    Ajduk J, Marinic I, Aberle N, Rabatic S, Gagro A. Effect of house dust mite immunotherapy on transforming growth factor beta1-producing T cells in asthmatic children. Ann Allergy Asthma Immunol. 2008;100:314–22.PubMedCrossRefGoogle Scholar
  33. 33.
    Radulovic S, Jacobson MR, Durham SR, Nouri-Aria KT. Grass pollen immunotherapy induces Foxp3-expressing CD4+ CD25+ cells in the nasal mucosa. J Allergy Clin Immunol. 2008;121:1467–72. 1472 e1461.CrossRefPubMedGoogle Scholar
  34. 34.
    Saito K, Torii M, Ma N, Tsuchiya T, Wang L, Hori T, et al. Differential regulatory function of resting and preactivated allergen-specific CD4+ CD25+ regulatory T cells in Th2-type airway inflammation. J Immunol. 2008;181:6889–97.PubMedGoogle Scholar
  35. 35.
    Thunberg S, Akdis M, Akdis CA, Gronneberg R, Malmstrom V, Trollmo C, et al. Immune regulation by CD4+CD25+ T cells and interleukin-10 in birch pollen-allergic patients and non-allergic controls. Clin Exp Allergy. 2007;37:1127–36.CrossRefPubMedGoogle Scholar
  36. 36.
    Cosmi L, Liotta F, Angeli R, Mazzinghi B, Santarlasci V, Manetti R, et al. Th2 cells are less susceptible than Th1 cells to the suppressive activity of CD25+ regulatory thymocytes because of their responsiveness to different cytokines. Blood. 2004;103(8):3117–3121.CrossRefPubMedGoogle Scholar
  37. 37.
    Stummvoll GH, DiPaolo RJ, Huter EN, Davidson TS, Glass D, Ward JM, et al. Th1, Th2, and Th17 effector T cell-induced autoimmune gastritis differs in pathological pattern and in susceptibility to suppression by regulatory T cells. J Immunol. 2008;181:1908–16.PubMedGoogle Scholar
  38. 38.
    Vissers JL, van Esch BC, Hofman GA, Kapsenberg ML, Weller FR, van Oosterhout AJ. Allergen immunotherapy induces a suppressive memory response mediated by IL-10 in a mouse asthma model. J Allergy Clin Immunol. 2004;113:1204–10.CrossRefPubMedGoogle Scholar
  39. 39.
    Caudy AA, Reddy ST, Chatila T, Atkinson JP, Verbsky JW. CD25 deficiency causes an immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like syndrome, and defective IL-10 expression from CD4 lymphocytes. J Allergy Clin Immunol. 2007;119:482–7.CrossRefPubMedGoogle Scholar
  40. 40.
    Dieckmann D, Bruett CH, Ploettner H, Lutz MB, Schuler G. Human CD4(+) CD25(+) regulatory, contact-dependent T cells induce interleukin 10-producing, contact-independent type 1-like regulatory T cells [corrected]. J Exp Med. 2002;196:247–53.CrossRefPubMedGoogle Scholar
  41. 41.
    Jonuleit H, Schmitt E, Kakirman H, Stassen M, Knop J, Enk AH. Infectious tolerance: human CD25(+) regulatory T cells convey suppressor activity to conventional CD4(+) T helper cells. J Exp Med. 2002;196:255–60.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Hanna Grindebacke
    • 1
  • Pia Larsson
    • 1
  • Kajsa Wing
    • 1
  • Sabina Rak
    • 2
  • Anna Rudin
    • 1
  1. 1.Department of Rheumatology and Inflammation Research, The Sahlgrenska AcademyUniversity of GothenburgGothenburgSweden
  2. 2.Department of Respiratory Medicine and Allergology, The Sahlgrenska AcademyUniversity of GothenburgGothenburgSweden

Personalised recommendations